14-Dec-2006

Novartis making significant progress in creating new strategic growth platform in human vaccines, names site for new division headquarters

 

 

28-Nov-2006

Novartis submits first regulatory file for H5N1 adjuvanted influenza vaccine with European regulators for pre-pandemic avian influenza prevention

 

 

20-Nov-2006

Novartis secures contract to supply additional H5N1 influenza vaccine to the US government

 

 

16-Nov-2006

Data from pivotal Phase III trial for new Japanese Encephalitis virus vaccine (IC51) show good immunogenicity, safety and tolerability profile

 

 

19-Oct-2006

Novartis MF59-adjuvanted influenza vaccine (FLUAD) data demonstrate significant protective benefits in adults at risk for post-influenza complications

 

 

19-Oct-2006

Pivotal Phase III trial results show Novartis cell culture-derived influenza vaccine well tolerated and efficacious

 

 

16-Aug-2006

Novartis releases Fluvirin influenza virus vaccine to US distributors

 

 

08-Aug-2006

Novartis MeNZB(TM) vaccine campaign data show 80 percent efficacy rate during epidemic meningococcal B disease outbreak in New Zealand

 

 

18-Jul-2006

Novartis to build latest-technology influenza vaccines manufacturing site in North Carolina

 

 

13-Jun-2006

Novartis expands late-stage vaccines pipeline with novel vaccine for prevention of Japanese Encephalitis virus infections

 

 

04-May-2006

Novartis awarded up to USD 220 million by US Department of Health and Human Services for development of cell culture-derived influenza vaccine

 

 

19-Apr-2006

Novartis acquisition of Chiron approved by Chiron shareholders